

# Annual Financial Report

---

For the period ending 31 December 2020

# Contents

---

<u>Information Register</u>	<u>4</u>
<u>Directors' Report</u>	<u>5</u>
<u>Results from Operations</u>	<u>9</u>
<u>Statement of Profit or Loss and Other Comprehensive Income</u>	<u>15</u>
<u>Statement of Financial Position</u>	<u>16</u>
<u>Statement of Changes in Funds</u>	<u>17</u>
<u>Statement of Cash Flows</u>	<u>18</u>
<u>Notes to the Financial Statements</u>	<u>19</u>
<u>Directors' Declaration</u>	<u>30</u>
<u>Auditor's Independence Declaration</u>	<u>31</u>
<u>Independent Audit Report</u>	<u>32</u>

# Information Register

---

## ABN

77 221 238 430

## Board of Directors

Role	Name
Chairman	Malcolm Day
Deputy-Chairman	Simon Martin
Director	Dr Corinne Jones
Director	Bonnie Bullock
Director	Ralph Winter
Director	Pauline Gately
Director	Adam Marshall
Director	Brendan Cooley
Director	Ellie Scarf

## Registered Office

80 Railway Street  
Cottesloe WA 6011

## Bankers

National Australia Bank  
464 Hay Street  
SUBIACO WA 6008

ANZ Bank  
1275 Hay Street  
WEST PERTH WA 6005

Bendigo Bank  
9 Adelaide St  
Fremantle WA 6160

Macquarie Bank  
1 Shelley Street  
Sydney NSW 2000

## Auditors

BDO Audit (WA) Pty Ltd  
38 Station Street  
SUBIACO WA 6008

# Directors' Report

Our directors present this report of Breast Cancer Care WA Inc.

## Board

The names of each person who has been a director during the period and at the date of the report are:

Name	Date Appointed	Date Ceased
Malcolm Day	2004	Current
Simon Martin	February 19, 2009	Current
Dr Corinne Jones	March 18, 2009	Current
Bonnie Bullock	May 16, 2012	Current
Ralph Winter	May 16, 2012	Current
Pauline Gately	March 19, 2014	Current
Adam Marshall	December 8, 2016	Current
Brendan Cooley	October 2020	Current
Ellie Scarf	October 2020	Current

## Principal Activities

Breast Cancer Care WA provides a supportive care service for those affected by breast cancer in Western Australia. It recognises that individuals have different needs and therefore require different levels of response. The supportive care provision is evidence-based and customised to meet the individual or family's needs, which may require liaison, collaboration, or referral to another agency.

The principal activities of Breast Cancer Care WA in the course of the period consisted of providing personalised emotional, practical and financial support to people affected by breast cancer and educating the community to increase awareness and early detection of breast cancer.

- **Breast Care Nurse Support:** in the home, at hospital and medical appointments and from our Cottesloe office. Our nurses assist clients in navigating health services, understanding their diagnosis and treatment plan, make informed decisions. If necessary, they can liaise and advocate with the treatment team on behalf of a client.
- **Counselling Support:** individual and couples counselling to those with a breast cancer diagnosis and their loved ones. Our counsellors help clients develop practical strategies to cope with distress, decision making, body image and sexuality concerns. They can also work with the client to improve communication with children and family members.

- **Financial Assistance:** this is available to those experiencing financial hardship due to their breast cancer. It can include a voucher to put food on the table, fuel in the car, or payment of a utility bill. It also includes assisting a person in accessing additional community support that will enable them to manage during an unavoidable period of extended hardship.
- **Practical Support:** this can include transport to and from appointments; cleaning, gardening, and childcare support.
- **Support Groups:** we run 16 monthly support groups for women across several metropolitan and regional locations. Groups are specific to the age and the stage of disease of the participants. There is also a dedicated support group for partners of people with breast cancer. These are professionally facilitated and use a mutual aid model where members share helpful information and coping strategies. During the COVID-19 pandemic we piloted the practice of conducting some of these groups online and based on the success, have continued with this practice into 2021.
- **Therapy Workshops:** we run one- and two-day workshops that use a range of therapeutic processes to assist clients in dealing with fear and uncertainty, communicating with family and loved ones and increasing their resilience.
- **Education:** we deliver talks in the community to raise awareness on the importance of the early detection of breast cancer, distribute support materials including breast self-examination guides and run health promotion articles via our social media. We provide individual client education and group client workshops and seminars to educate and empower clients living with a new or recurrent, or metastatic cancer to better self-manage distress and wellbeing.
- **Referrals and connections:** we work closely with health professionals in the

breast cancer treatment centres, including breast surgeons, oncologists, GPs, breast care nurses, social workers, lymphoedema therapists, as well as Cancer Council Western Australia and Breast Cancer Network Australia to refer clients to existing services and broaden their support network. In 2020, 66% of our new clients were referred by a health professional.

## Emotional Support

Our team of five specialist Breast Care Nurses, four Counsellors, Client Support Coordinator and Support Services Manager play a vital role in providing emotional support and information at various phases across the continuum of care, including diagnosis, treatment, rehabilitation, follow-up, survivorship, and palliative care.

We continue to experience high demand for our Support Services, and the number of clients to whom we are providing support remains consistent. 941 individuals accessed our service in 2020 (1041 in 2019), and our team provided 12,025 occasions of support to clients and their families. 627 new clients were admitted to our service. 465 had primary breast cancer, 113 had a metastatic breast cancer and 23 were family members of someone with breast cancer. 276 of the new clients accessed Breast Care Nursing support, 346 accessed counselling, 59 accessed a support group and 140 accessed financial or practical assistance. The complexity of many client cases has meant that each client requires a wide range of support services and increased ongoing support. The average time that a client remains engaged with our service is 2 years.

In 2020 the COVID-19 pandemic created several challenges for people undergoing treatment for cancer, and we identified a significant increase in distress amongst our clients. Clients became very comfortable with telehealth services, and our nurses and counsellors became proficient at providing information and emotional support via telephone and video calls.

18% of our new clients in 2020 had a metastatic breast cancer diagnosis. To meet their unique needs, we maintained our dedicated

metastatic breast care nurse and counselling support. We extended the metastatic support groups to include a group in Bunbury and a virtual group for young women. Also, we increased the amount of financial and practical support available to this group of clients.

Our Counsellors facilitated 16 monthly support group meetings throughout the metropolitan area, reaching as far as Bunbury: six for those with early breast cancer (EBC), three for young women with EBC (including online), five for those with metastatic breast cancer, one for young women with metastatic breast cancer, and a partners' support group. Studies have identified that support groups help participants feel less distressed, less alone, and more optimistic about the future, hence our investment in providing a wide range of group meetings. 139 clients attended a regular support group in 2020, with 102 support group meetings held across the year. COVID-19 pandemic restrictions between March and June required us to conduct virtual groups, which the younger women's groups adapted to well.

Therapeutic workshops were held from October when the COVID-19 restrictions allowed for more face-to-face connection. 14 couples attended a weekend workshop. 14 attended clay therapy workshops, and 14 attended a Stress Management Strategies workshop.

## Practical Support

### Practical Assistance:

Following surgery and during treatment, we provide help with basic living needs, including transport to and from appointments, help with looking after children, cleaning, and gardening. We provide practical assistance to clients with advanced breast cancer waiting for Centrelink support. In 2020 we provided 112 clients with practical support. This included 136 occasions of transport, 510 hours of cleaning and 23 hours of gardening.

### Information and Referrals:

We operate as an information service and provide referrals to other agencies for specialist financial advice, legal and return to work advice, wigs, prosthesis and lymphoedema treatment.

### Financial Support

A breast cancer diagnosis can have a severe financial impact, especially if a client cannot work during treatment. In 2020 226 clients accessed our financial assistance program. We processed 443 financial assistance requests and provided 1053 vouchers to put food on the table and 340 vouchers to put fuel in the car, enabling clients to get to medical and treatment appointments.

### Education Programs


Early detection of breast cancer is vital to ensure the best chance of successful treatment. Our education and awareness initiatives seek to teach people of all ages to be breast aware and develop good breast health habits. Additionally, our Nurses and Counsellors provide education support to our clients, their families, and carers, to equip them with information and experiences that support their quality of life.

As a West Australian charity supporting people diagnosed with breast cancer, along with their family members and carers, at Breast Cancer Care WA we operate in the spirit of collaboration. This is evidenced in our participation as a founding member charity of the Cancer Wellness Centre and our work with many other great organisations to provide the best and most comprehensive support service possible to people affected by breast cancer.



bre  
C

*Thank you!*



# Results from Operations

## Operations Review

Comprehensive Income of \$ 24,940 was made during January to December 2020 compared to the budgeted deficit of \$ 345,915.

The application of costs for the period ended 31 December 2020 was as follows:

Employment Costs:	47%
Operational Cost:	9%
Administration Costs	5%
Fundraising Costs:	7%
Growth Initiatives	32%
Total Applied Funds	100%

*Further details of Breast Cancer Care WA Inc. results can be found in notes 4 and 5 to the financial statements*

2020 commenced as the year we planned on celebrating our 20<sup>th</sup> year of supporting people in WA facing breast cancer. With the onset of the COVID-19 worldwide pandemic early on, the strategy quickly became one of delivering continuity of support to our clients in a lockdown environment at a heightened time of anxiety, fear and stress, and managing the significant loss of fundraising revenue due to cancelled events and fundraisers. As we reflect on the year, we are pleased to report that not one day of interruption occurred to service delivery, and that whilst in-person contact was put on hold, our clients and our team made the shift to online support service delivery with minimal challenges.

As an organisation dedicated to providing personalised support services tailored to the needs of each individual client, our greatest

expense and our greatest asset is our Team, without whom our Support Services would not be possible. In the uncertainty of the pandemic, we are also proud that we met our goal of zero job loss for our team.

Expenses were significantly reduced wherever possible to minimise the impact of the challenging fundraising period, and to position the organisation for a strong start to 2021, as evidenced by the net surplus result against a budgeted deficit of \$345,915.

In 2020, we continued with our growth initiatives strategy to encourage donors to make regular monthly contributions so that we can be assured of sustainable income to fund our vital services. This strategy requires significant upfront costs, which we recognised would be high at the outset, and we carefully weighed our decision against the expected benefit of the future income streams and the resources available to us. Almost five years into the program, targets are being met and key indicators continue to perform as originally planned. We are confident that the implementation of our growth initiatives strategy was and remains a sound decision.

The reported income in operations of \$24,941 (\$370,856 better than budgeted) is the result of strong financial management throughout the year, savings in growth initiatives expenses and government stimulus payments during COVID-19.

With over 1,700 people in WA diagnosed with breast cancer each year, it is vital that we not only invest in delivering support services today, but also in creating sustainable income sources to allow us to be here for those affected in the future.

Cash and invested funds at 31 December 2020 total **\$2,076,806** (31 December 2019 **\$1,954,670**).



## Strategic Horizon

We continue to endeavour to meet and surpass our goals in providing support services for all West Australians whose lives have been affected by breast cancer. At the time of writing this report, the COVID-19 pandemic continues to create significant uncertainty, with Western Australia experiencing two snap lockdowns already in 2021. Breast Cancer Care WA, like many great causes, anticipates that the pandemic may continue to impact fundraising events; however, the Directors and CEO are confident that ongoing sound financial management will maintain support services delivery at current levels, and that the organisation will move strongly into the future.

Signed in accordance with a resolution of the directors.

For and on behalf of the Board:



**Malcolm Day**

Director and Chairman  
29 June 2021



**Simon Martin**

Director and Vice-Chairman  
29 May 2021

# Directors



## Malcolm Day Chairman

**Bachelor of Applied Science Surveying and Mapping,  
Licensed Surveyor**

Previously employed as a Senior Civil Engineer. Non-executive Director of European Lithium Ltd (listed on the Australian, German and Austrian Stock Exchanges), a member of the Australian Institute of Company Directors. Managing Director of Delecta Ltd (listed on the Australian Stock Exchange). Founder and owner of the annual Boobalicious Ball.

**Special Responsibilities: Chairman, Investment Committee**



## Simon Martin Vice Chairman

**BComm, CA GAICD**

An executive with over 20 years' experience across all facets of business management. Simon's previous roles include General Manager for Network Ten Perth and CEO for Cystic Fibrosis Australia. Simon is currently the Chief Financial Officer for WA Primary Health Alliance.

**Special Responsibilities: Vice Chairman, Investment Committee**



## Dr Corinne Jones

**MBBS (UWA) FRACS FRCS**

Full time, private Breast, Thyroid & Parathyroid Surgeon, working and consulting at St John of God Hospital in Subiaco.

**Special Responsibilities: Professional Recognition,  
Personalised Care**

## Bonnie Bullock

**BArts. Member of PRIA**

Director of Saranac PR. Bonnie has worked in public relations for over 20 years spanning the USA, Sydney, and Perth. Bonnie has extensive experience in media relations, issues + crisis management and corporate profiling.

**Special Responsibilities: Marketing and Communications**



## Ralph Winter

**BComm, GAICD, Post Grad Prof Acct**

Commercial Director and Company Secretary of Moho Resources Ltd; Ralph has worked for 16 years in various industries (mostly mining) with extensive commercial experience and a strong focus on finance acquisition, public and investor relations, business management and marketing.

**Special Responsibilities: Investment Committee**



## Pauline Gately

**BA Hons (Econ), Grad Dip Acc, GAICD**

A highly accomplished economist, investment strategist and Non-Executive Director, Pauline, has experience across a range of Board positions in mining and resources, financial technology, and FMCG. Pauline has a track record of successfully navigating changing directional points. Her Board contributions are underpinned by senior roles in international investment banking, including investment strategy and funds management. A graduate of the Australian Institute of Company Directors, Pauline is currently Non-Executive Chair of Australian Primary Hemp Ltd (ASX:APH) and Non-Executive Director of Ardiden Ltd (ASX:ADV).

**Special Responsibilities: Investment Committee**



## Adam Marshall

### 2:1 BA Economics, Goldsmiths College, University of London



Adam is the Chief Executive Officer of Marketforce Group, a member of the Clemenger BBDO Network. He has over twenty years marketing experience and has worked in the UK and Asian markets. He is a regular commentator on advertising matters in the broader media and has lectured on advertising and marketing at each of Perth's universities and at AdSchool.

Adam has previously been Chairperson of the Oasis Committee the WA advertising industry's charity association and is a board member of charity FTT, a group dedicated to raising funds for disabled athletes.

### Special Responsibilities: Marketing and Communications

## Ellie Scarf

### BA, LLB



Ellie is a Senior Partner and the Managing Director for Australia, at OSC Leadership Development. She is an Executive Coach, Leadership Consultant and business owner with a passion for evidence based approaches to optimising individual, team and organizational performance.

Ellie has worked in people focussed roles for the past 15 years, including coaching and facilitating, leading sales capability and strategy within a billion dollar organisation, learning and development roles and being part of a human centred innovation team. Ellie is also a qualified lawyer who started her career within top tier law firms in WA and NSW

### Special Responsibilities: People and culture

## Brendan Cooley

### MBA (Leadership), GAICD, Graduate Certificate in Business, Diploma Transport & Distribution



Brendan is an accomplished Director with broad and strategic experience across a portfolio of Board positions. Currently Managing Director at International Maritime Services Pty Ltd (IMS), a privately held maritime services company based in Perth WA, Brendan joined the Breast Cancer Care WA board in October 2020.

A *40 under 40* winner with post-graduate qualifications in leadership, business administration, and transport and logistics, Brendan has substantial experience in the marine and tourism industries in diverse roles including commercial, operations, corporate development, and sustainability.

With 10 years' executive experience across private sector and community organizations, he operates with a strong emphasis on advocacy, governance, and strategy, particularly within dynamic or challenging business environments.



# Statement of Profit or Loss and Other Comprehensive Income

FOR THE YEAR ENDED 31 DECEMBER 2020

	Notes	31 Dec 2020	31 Dec 2019
		\$	\$
<b>INCOME</b>			
Fundraising Income	4a	2,897,671	3,216,318
Investment Income	4b	59,209	185,690
Other Income	4c	608,943	-
<b>Total Revenue &amp; Other Income</b>		<b>3,565,823</b>	<b>3,402,008</b>
<b>EXPENDITURE</b>			
<i>Operational</i>		(335,980)	(344,419)
<i>Fundraising</i>		(257,124)	(565,403)
<i>Administration</i>		(160,412)	(93,454)
<i>Employment</i>	5	(1,668,047)	(1,701,522)
<i>Growth Initiatives</i>		(1,119,319)	(474,008)
<b>Total</b>		<b>(3,540,882)</b>	<b>(3,178,806)</b>
<b>Net surplus (loss) for the year</b>		<b>24,941</b>	<b>223,202</b>
<b>Total Comprehensive Income/ (expense) for the year</b>		<b>24,941</b>	<b>223,202</b>

The statement of profit or loss and other comprehensive income is to be read in conjunction with the attached notes.

# Statement of Financial Position

FOR THE YEAR ENDED 31 DECEMBER 2020

	Notes	31 Dec 2020	31 Dec 2019
		\$	\$
<b>ASSETS</b>			
<b>Current Assets</b>			
Cash and cash equivalents	6	1,039,660	840,315
Trade and other receivables	7	87,301	87,584
Prepayments		23,631	34,891
<b>Total Current Assets</b>		<b>1,150,592</b>	<b>962,790</b>
<b>Non-Current Assets</b>			
Plant and equipment	8a	92,234	92,944
Financial Assets	9	1,037,146	1,114,355
Right of Use Assets	8b	104,955	126,645
<b>Total Non-Current Assets</b>		<b>1,234,335</b>	<b>1,333,944</b>
<b>TOTAL ASSETS</b>		<b>2,384,927</b>	<b>2,296,734</b>
<b>LIABILITIES</b>			
<b>Current Liabilities</b>			
Trade and other payables	10	192,972	124,744
Provisions	11	119,794	105,522
Lease Liabilities	12	28,141	25,739
<b>Total Current Liabilities</b>		<b>340,907</b>	<b>256,005</b>
<b>Non-Current Liabilities</b>			
Provisions	11	27,389	24,947
Lease Liabilities	12	76,814	100,906
<b>Total Non-Current Liabilities</b>		<b>104,203</b>	<b>125,853</b>
<b>TOTAL LIABILITIES</b>		<b>445,110</b>	<b>381,858</b>
<b>NET ASSETS</b>		<b>1,939,817</b>	<b>1,914,876</b>
<b>FUNDS</b>			
General Funds		1,939,817	1,914,876
<b>TOTAL FUNDS</b>		<b>1,939,817</b>	<b>1,914,876</b>

The statement of financial position is to be read in conjunction with the attached notes.

# Statement of Changes in Funds

FOR THE YEAR ENDED 31 DECEMBER 2020

	General Funds	Total Funds
	\$	\$
Balance at 1 January 2019	1,691,674	1,691,674
Net surplus	223,202	223,202
<b>Balance at 31 December 2019</b>	<b>1,914,876</b>	<b>1,914,876</b>
Balance at 1 January 2020	1,914,876	1,914,876
Net surplus	24,941	24,941
<b>Balance at 31 December 2020</b>	<b>1,939,817</b>	<b>1,939,817</b>

*The statement of changes of funds is to be read in conjunction with the attached notes.*



# Statement of Cash Flows

## FOR THE YEAR ENDED 31 DECEMBER 2020

	Notes	31 Dec 2020 \$	31 Dec 2019 \$
<i>Cash flows from operating activities</i>			
Receipts from:			
Fundraising Income		2,961,496	3,233,334
Investment Income		34,491	43,056
Other Income		608,943	-
<b>Payments to suppliers &amp; employees</b>		<b>(3,557,900)</b>	<b>(3,137,668)</b>
Cash flows from other operating activities		93,472	50,056
<b>Net cash from/(used in) operating activities</b>	<b>13</b>	<b>140,502</b>	<b>188,778</b>
<i>Cash flows from investing activities</i>			
Purchase of property plant and equipment		(18,283)	(3,526)
Purchase of Financial Assets		(24,966)	(232,936)
Sale of Financial Assets		115,598	290,123
<b>Net cash from/(used in) investing activities</b>		<b>72,349</b>	<b>53,661</b>
<i>Cash flows from financing activities</i>			
Other cash items from financing activities		19,186	-
Lease Payments (principal and interest)		(32,691)	(34,335)
<b>Net cash from/(used in) financing activities</b>		<b>(13,505)</b>	<b>(34,335)</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>		<b>199,345</b>	<b>208,104</b>
Cash and cash equivalents at the beginning of the year		840,315	632,211
<b>Cash and cash equivalents at the end of the year</b>	<b>6</b>	<b>1,039,660</b>	<b>840,315</b>

The statement of cash flows is to be read in conjunction with the attached notes.

# Notes to the Financial Statements

## FOR THE YEAR ENDED 31 DECEMBER 2020

### 1. CORPORATE INFORMATION

The financial statements of the not-for-profit entity, Breast Cancer Care WA Inc for the year ended 31 December 2020 were authorised for issue in accordance with a resolution of the directors on 29 June 2021.

Breast Cancer Care WA Inc. is an incorporated association operating exclusively in Australia. The nature of the entity's operations and principal activities are described in the director's report.

### 2. CHANGES IN ACCOUNTING POLICIES

The accounting policies and methods of computation adopted in the preparation of the previous year's financial report are consistent with those adopted and disclosed in the entity's annual financial report for the financial year ended 31 December 2020, except for the application of the following standards for the first time:

#### AASB 20-4 COVID-19-Related Rent Concessions

The Australian Accounting Standards Board issued AASB 2020-4 Amendments to Australian Accounting Standards - COVID-19-Related Rent Concessions (Amendment to AASB 16) on 15 June 2020. This Standard amends AASB 16 to provide a practical expedient that permits lessees not to assess whether rent concessions that occur as a direct consequence of the COVID-19 pandemic and meet specified conditions are lease modifications and, instead, to account for those rent concessions as if they were not lease modifications. This Standard applies to annual periods beginning on or after 1 June 2020. Earlier application is permitted,

including in financial statements not authorised for issue at the date this Standard was issued.

The practical expedient applies only to rent concessions occurring as a direct consequence of COVID-19 and only if all the following conditions are met:

- The change in lease payments results in revised consideration for the lease that is substantially the same as, or less than, the consideration for the lease immediately preceding the change.
- Any reduction in lease payments affects only payments originally due on or before 30 June 2021 (a rent concession will meet this condition if it results in reduced lease payments on or before 30 June 2021 and increased lease payments that extend beyond 30 June 2021)
- There is no substantive change to other terms and conditions of the lease.

In the current year, the directors have elected to apply AASB 2020-4 Amendments to Australian Accounting Standards - COVID-19 Related Rent Concessions before its mandatory application date. AASB 2020-4 amends AASB 16 Leases and is effective for annual periods that begin on or after 1 June 2020.

Breast Cancer Care WA Inc has elected to apply the practical expedient to all the COVID-19-related rental concessions it has obtained as lessee. The amount totaling \$15,743 recognised in profit or loss for the reporting period to reflect changes in lease payments that arise from rent concessions.

These accounting policies are consistent with Australian Accounting Standards and with International Financial Reporting Standards.

### 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### (a) Basis of preparation

These general-purpose financial statements have been prepared in accordance with the requirements of the Associations Incorporations Act [WA], Australian Accounting Standards – Reduced Disclosure Requirements, other authoritative pronouncements of the Australian Standards Board, Urgent Issues Group Interpretations and the ACNC Act 2012.

The directors have determined that Breast Cancer Care WA Inc is permitted to apply the Tier 2 reporting requirements (Australia Accounting Standards – Reduced Disclosure Requirements) as set out in AASB 1053 Application of tiers of Australian Accounting Standards because it is a not-for-profit private sector entity that does not have public accountability. The authorisation for the issue of these accounts is in accordance with a resolution of the directors on 29 June 2021.

#### Historical Cost Accounting.

The financial statements have been prepared on the basis of historical cost.

#### Functional Currency.

The financial report is presented in Breast Cancer Care WA Inc.'s functional currency which is the Australian dollar.

#### (b) Significant accounting judgements, estimates and assumptions

The preparation of financial statements requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income, and expenses. The estimates and associated assumptions are based on historical experience and other various factors

that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.

#### Significant accounting estimates and assumptions

The key estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of certain assets and liabilities within the next annual reporting period are:

#### Provisions for employee benefits

Provisions for employee benefits payable after 12 months from the reporting date are based on future wage and salary levels, experience of employee departures and periods of service, as discussed in Note 3(l).

The amount of these provisions would change should any of these factors change in the next 12 months.

#### (c) Revenue recognition

Revenue is recognised under AASB 1058 or AASB 15 when appropriate. In cases where there is an enforceable' contract with a customer with 'sufficiently specific' performance obligations, the transaction is accounted for under AASB 15 where income is recognised when (or as) the performance obligations are satisfied (i.e.) when it transfers control of a product or service to a customer). Revenue is measured based on the consideration to which the Breast Cancer Care WA expects to be entitled in a contract with

parties. In other cases, AASB 1058 applies when a NFP entity enters into transactions where the consideration to acquire an asset is significantly less than the fair value of the asset principally to enable the entity to further its objectives and the excess of the asset recognised (at fair value) over any 'related amounts' is recognised as income immediately.

#### **(i) Donations & Growth Initiatives**

Donations collected, including cash and goods for resale, are recognised as revenue when the Breast Cancer Care WA gains control of the asset.

#### **(ii) Investment income**

Investment income comprises interest, dividends, trust distributions and realised gains on investments. Interest income is recognised as it accrues, using the effective interest method. Dividends and distributions from entities are recognised when the shareholder's right to receive payment has been established, provided it is probable that the economic benefits will flow to the entity and the amount of income can be measured reliably.

#### **(iii) Sale of Goods**

Revenue from the sale of goods is measured at fair value received or receivable and is recognized when control of the goods passes to the customer.

#### **(iv) Sponsorships & Grants**

Sponsorships and grants are recognised when there is reasonable assurance that the grant will be received, and all attaching conditions have been complied with.

Under AASB 1004, most grant income was recognised as revenue on receipt. Under AASB 1058 and AASB 15, where an agreement is enforceable and contains sufficiently specific performance obligations, the revenue is either recognised over time as the work is performed or recognised at the point in time that the control of the services pass to the customer.

Having reviewed the grants received, The Directors have determined that no grants provided to the entity during the period create a sufficiently specific and enforceable contract to require a change in treatment from prior periods.

#### **(v) Volunteer Services**

The Directors have decided not to recognise volunteer services within the financial statements, given the true value of these services is not reliably measurable in financial terms.

#### **(d) Expenditure**

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Where costs cannot be directly attributed to a particular category, they have been allocated to activities on a basis consistent with use of the resources.

Fundraising costs are those incurred in seeking voluntary contributions by donation and do not include costs of disseminating information relating to the activities carried on by the entity. Costs incurred in obtaining regular donations are expensed in full when the donor is registered to make a future donation. These costs have been disclosed as growth initiatives in the Financial Statements.

Operational costs are those costs directly incurred in supporting the objects of the entity.

Administration costs are those costs incurred in connection with administration of the entity and compliance with constitutional and statutory requirements.

Employment costs have been incurred in order to service the operational activities of the entity, predominantly the professional team to deliver support services to people affected by breast cancer, administer those services and assist with fundraising activities and the coordination of volunteers. An allocation of employment costs to each category is provided at note 5.

#### **(e) Cash and cash equivalents**

Cash and short-term deposits in the statement of financial position is comprised of cash at bank and in hand, and short-term deposits with an original maturity of six months or less.

For the purposes of the Statement of Cash Flows, cash and cash equivalents consist of cash and cash equivalents as defined above, net of outstanding bank overdrafts.

## (f) Trade and other receivables

Trade receivables, which generally have 30–90-day terms, are recognised and carried at original invoice amount less an allowance for any uncollectible amounts.

Breast Cancer Care WA applies the AASB 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables. Bad debts are written off when identified.

Other receivables include donations which are accrued when it is probable that funds will be received and can be reliably measured.

## (g) Plant and Equipment

Plant and equipment is stated at cost less accumulated depreciation and any accumulated impairment losses.

Depreciation is calculated on a straight-line basis over the estimated useful life of the assets as follows:

- Plant and equipment 3 to 5 years
- Motor Vehicles 5 years

The assets' residual values, useful lives and amortisation methods are reviewed, and adjusted if appropriate, at each financial period.

### Impairment

The carrying values of plant and equipment are reviewed for impairment at each reporting date, with recoverable amount being estimated when events or changes in circumstances indicate that the carrying value may be impaired.

The recoverable amount of plant and equipment is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

For an asset that does not generate largely independent cash inflows, recoverable amount is determined for the cash-

generating unit to which the asset belongs, unless the asset's value in use can be estimated to be close to its fair value.

Impairment exists when the carrying value of an asset or cash-generating units exceeds its estimated recoverable amount. The asset or cash-generating unit is then written down to its recoverable amount.

## (h) Financial assets

### Recognition, initial measurement and derecognition

Financial assets are recognised when Breast Cancer Care becomes a party to the contractual provisions of the financial instrument and are measured initially at fair value adjusted by transactions costs, except for those carried at fair value through profit or loss, which are measured initially at fair value. Subsequent measurement of financial assets is described below.

The fair value of investments that are actively traded in organised financial markets is determined by reference to quoted market bid prices at the close of business on the reporting date. For investments with no active market, fair value is determined using valuation techniques. Such techniques include using recent arm's length market transactions, reference to the current market value of another instrument that is substantially the same, discounted cash flow analysis and option pricing mode.

Financial assets are derecognised when the contractual rights to the cash flows from the financial asset expire, or when the financial asset and all substantial risks and rewards are transferred.

### Classification of financial assets

Classifications are determined by both:

- The business model for managing the financial asset
- The contractual cash flow characteristics of the financial assets

### **Classification and subsequent measurement of financial assets**

Under AASB 9, the basis on which the financial assets are measured is relevant to the way they are classified. The identification can be initiated by an assessment of the following critical issues in relation to these assets:

- The objective of the entity's business model is to hold these assets only to collect cash flows, or to collect cash flows and to sell ("The Business Model Test") and
- The contractual cash flows of the assets give rise to contractual payments that are solely payments of principal and interest ("SPPI Test")

Both tests must be met in order to classify and measure the asset at:

- Amortised Cost
- Equity instruments at Fair Value through Other Comprehensive Income (FVOCI)

Failing these tests requires the assets to be classed and measured at Fair Value through Profit & Loss (FVPL).

### **Financial assets at fair value through profit or loss (FVPL)**

Financial assets that are held within a different business model other than 'hold to collect' or 'hold to collect and sell' are categorised at fair value through profit and loss. Further, irrespective of business model financial assets whose contractual cash flows are not solely payments of principal and interest are accounted for at FVPL.

Given that the business model and contractual cash flows of the assets differ from the above tests, Breast Cancer Care WA has categorised the equity investments on hand at fair value through profit and loss.

### **(i) Impairment of financial assets at fair value through profit and loss**

Breast Cancer Care WA follows the guidance of AASB 9 Financial Instruments to determine when a financial asset is impaired. The only

impairment methodology under this standard uses more forward-looking information to measure the impairment under the 'Expected Credit Losses (ECL) model. Instruments within the scope of this model include financial assets measured at amortised cost and FVOCI.

### **(j) Trade and other payables**

Trade payables and other payables are carried at amortised costs and represent liabilities for goods and services provided to Breast Cancer Care WA prior to the end of the period that are unpaid and arise when Breast Cancer Care WA becomes obliged to make future payments in respect of the purchase of these goods and services.

### **(k) Provisions**

Provisions are recognised when Breast Cancer Care WA has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

When Breast Cancer Care WA expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognised as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the statement of comprehensive income net of any reimbursement.

If the effect of the time value of money is material, provisions are discounted using a pre-tax rate that reflects the risks specific to the liability. When discounting is used, the increase in the provisions due to the passage of time is recognised as a borrowing cost.

### **(l) Employee entitlements**

#### **(i) Wages, salaries, annual leave, and sick leave**

Liabilities for wages and salaries, including non-monetary benefits, annual leave and accumulating sick leave expected to be settled within 12 months of the reporting date are

recognised in other payables in respect of employees' services up to the reporting date. They are measured at the amounts expected to be paid when the liabilities are settled. Liabilities for non-accumulating sick leave are recognised when the leave is taken and are measured at the rates paid or payable.

#### **(ii) Long service leave**

The liability for long service leave is recognised in the provision for employee benefits and measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method.

Consideration is given to the expected future salaries and wage levels, experience of employee departures and periods of service.

#### **(m) Income tax**

Breast Cancer Care WA Inc. is exempt from the payment of income tax under the provisions of Section 50-45 of the Income Tax Assessment Act 1997. **The entity holds deductible gift recipient status.**

#### **(n) Other taxes**

Revenues, expenses and assets are recognised net of the amount of GST except:

- when the GST incurred on a purchase of goods and services is not recoverable from the taxation authority, in which case the GST is recognised as part of the cost of acquisition of the asset or as part of the expense item as applicable; and
- receivables and payables, which are stated with the amount of GST included.

The net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the statement of financial position.

Cash flows are included in the Statement of Cash Flows on a gross basis and the GST component of cash flows arising from investing and financing activities, which is recoverable

from, or payable to, the taxation authority are classified as operating cash flows.

Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the taxation authority.

#### **(o) Government Grants**

Other income comprises government grants for JobKeeper payments, ATO Cash Stimulus and Covid19 Rent Abatement.

##### **i. JobKeeper Payments**

The JobKeeper Payment Scheme was a subsidy for businesses significantly affected by coronavirus (Covid-19). The organisation was eligible to receive the subsidy as the operation satisfied the original and subsequent decline in turnover tests. Breast Cancer Care WA nominated all eligible employees and received payments until the end of the first extension period. This has been recognised as other income in the profit and loss on a cash received basis as disclosed at note 4(c).

##### **ii. COVID-19 Boosting Cash Flow**

On 24 March 2020, the Government introduced a new measure to provide temporary cash flow support to small to medium sized businesses and not-for-profit (NFP) organisations that employed staff during the economic downturn associated with COVID-19 (novel coronavirus). The amount was received entirely during the period and included as other income as disclosed at note 4(c).

	31 Dec 2020	31 Dec 2019
<b>4. INCOME</b>	<b>\$</b>	<b>\$</b>
(a) Fundraising Income:		
Donations & Growth Initiatives	2,562,615	2,902,226
Sponsorships and grants	335,056	314,092
	<b>2,897,671</b>	<b>3,216,318</b>
(b) Investment Income		
Interest income	3,805	2,888
Other investment income	41,980	55,465
Net gain/(loss) on disposal of Financial Assets	13,084	7,887
Change in FV of Available for Sale	340	119,449
	<b>59,209</b>	<b>185,690</b>
(c) Other Income		
Cash Stimulus Covid19	100,000	-
JobKeeper Covid19	493,200	-
Rent abatement Covid19	15,743	-
	<b>608,943</b>	<b>-</b>
	<b>31 Dec 2020</b>	<b>31 Dec 2019</b>
<b>5. EMPLOYMENT</b>	<b>\$</b>	<b>\$</b>
Operational	(971,969)	(976,628)
Fundraising	(428,925)	(468,199)
Administrative	(167,520)	(172,298)
Growth Initiatives	(99,633)	(84,397)
	<b>(1,668,047)</b>	<b>(1,701,522)</b>
	<b>31 Dec 2020</b>	<b>31 Dec 2019</b>
<b>6. CASH AND CASH EQUIVALENTS</b>	<b>\$</b>	<b>\$</b>
Cash at bank and in hand	610,289	535,783
Short-term deposits	429,371	304,532
	<b>1,039,660</b>	<b>840,315</b>

Cash at bank earns interest at floating rates based on daily bank deposit rates. Short-term deposits are made for varying periods of between one day and six months, depending on the immediate cash requirements of Breast Cancer Care WA, and earn interest at the respective short-term deposit rates.



	31 Dec 2020	31 Dec 2019
	\$	\$
<b>7. TRADE AND OTHER RECEIVABLES</b>		
Pledges Receivable	26,126	65,010
Net goods & services tax receivable	50,256	10,690
Other receivables	10,919	11,884
	<b>87,301</b>	<b>87,584</b>

Trade receivables, which generally have 30-90 day terms, are recognised and carried at original invoice amount less an allowance for any uncollectible amounts. Breast Cancer Care WA applies the AASB 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables. Bad debts are written off when identified.

## 8. PLANT AND EQUIPMENT AND RIGHT OF USE ASSETS

(a) Plant and Equipment	Furniture & Fixtures	Office Equipment	Trademarks & Licences	Total
	\$	\$	\$	\$
<b>COST OR FAIR VALUE</b>				
At 31 December 2019	124,769	111,378	510	236,657
Additions	-	18,284	-	18,284
Disposals	-	-	-	-
At 31 December 2020	124,769	129,662	510	254,941
<b>ACCUMULATED DEPRECIATION</b>				
At 31 December 2019	46,683	97,030	-	143,713
Depreciation charge for the period	9,083	9,911	-	18,994
Disposals	-	-	-	-
At 31 December 2020	55,766	106,941	-	162,707
<b>NET CARRYING AMOUNT</b>				
At 31 December 2019	78,086	14,348	510	92,944
At 31 December 2020	69,003	22,721	510	92,234

(b) Right of Use Assets	Buildings	Other	Total
	\$	\$	\$
At 31 December 2019	126,645	-	126,645
Right of Use Assets			
Depreciation Charge	(28,170)	-	(28,170)
Additions to Right of Use Assets	6,480	-	6,480
At 31 December 2020	104,955	-	104,955

## 9. FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT & LOSS (FVPL) - (NON CURRENT)

	31 Dec 2020	31 Dec 2019
	\$	\$
Listed investments at fair value in:		
Fixed Interest Investments	285,109	303,429
Equity Investments	613,272	667,233
Alternative Investments	138,765	143,693
	<b>1,037,146</b>	<b>1,114,355</b>
Movement in financial assets at FVPL		
Beginning balance	1,114,355	1,044,205
Purchases	4,256	208,548
Net disposal of Financial Assets	(81,805)	(257,847)
Changes in Fair Market Value	340	119,449
<b>Balance at the end of the year</b>	<b>1,037,146</b>	<b>1,114,355</b>

All Shares have no fixed maturity date or coupon rate. Fixed-interest-securities include corporate bonds, convertible notes and hybrid securities which have coupon rates varying from 2 per cent to 6 per cent and maturity dates ranging from November 2020 to April 2075. The market value of these securities fluctuates from time to time.

## 10. TRADE AND OTHER PAYABLES (CURRENT)

	31 Dec 2020	31 Dec 2019
	\$	\$
Visa Cards	19,568	11,638
Trade Creditors	67,425	12,685
Other Creditors	21,433	21,664
Accruals	84,546	78,757
	<b>192,792</b>	<b>124,744</b>

Trade and other payables are carried at amortised costs and represent liabilities for goods and services provided to Breast Cancer Care WA prior to the end of the period that are unpaid and arise when Breast Cancer Care WA becomes obliged to make future payments in respect of the purchase of these goods and services.

## 11. PROVISIONS

	31 Dec 2020	31 Dec 2019
	\$	\$
Current		
Employee entitlements – annual leave	91,131	76,859
Employee entitlements – long service leave	28,663	28,663
	<b>119,794</b>	<b>105,522</b>
Non – Current		
Employee entitlements – long service leave	27,389	24,947
	<b>27,389</b>	<b>24,947</b>

## 12. LEASE LIABILITIES

	31 Dec 2020	31 Dec 2019
	\$	\$
Current	28,141	25,739
Non - Current	76,814	100,906
	<b>104,955</b>	<b>126,645</b>

## 13. RECONCILIATION OF NET SURPLUS FOR THE PERIOD TO NET CASH FLOW FROM OPERATIONS

	Note	31 Dec 2020	31 Dec 2019
		\$	\$
Net Surplus/(loss) for the period		24,941	223,202
Depreciation	8	18,994	18,827
Changes in Fair Value of Financial Assets	9	(340)	(119,449)
Net loss/(gain) on disposal of Financial Assets		(13,084)	(7,888)
Lease payments showing as financing		32,691	34,335
Book Value of Donated Asset			469
(Increase)/Decrease in Assets			
Receivables		283	1,204
Prepayments		11,260	(5,559)
Increase/(Decrease) in Liabilities			
Trade creditors and accruals		49,042	(2,671)
Provision for employee benefits		16,714	46,308
<b>Net cash inflow from/(used in) operating activities</b>		<b>140,501</b>	<b>188,778</b>

## 14. RELATED PARTIES AND RELATED PARTY TRANSACTIONS

### (a) Directors' compensation

The directors act in an honorary capacity and receive no compensation for their services.

### (b) Key management personnel

The compensation paid to those having authority for planning, directing and controlling the entity's activities, directly or indirectly (other than directors), during the year:

	31 Dec 2020	31 Dec 2019
	\$	\$
Short – term employment benefits	306,938	381,591

## 15. AUDITOR'S REMUNERATION

Amounts received or due and receivable by auditors BDO Audit (WA) Pty Ltd of Breast Cancer Care WA Inc. for:

	31 Dec 2019	31 Dec 2019
	\$	\$
- an audit of the financial statements	4,120	3,500

## 16. CONTINGENT ASSET AND CONTINGENT LIABILITIES

The directors are not aware of any Contingent Assets and Contingent Liabilities that existed as of 31 December 2020.

## 17. COMMITMENTS

The directors are not aware of any commitments, other than those already disclosed, that existed at 31 December 2020.

# Directors' Declaration

The directors of Breast Cancer Care WA Inc declare that:

1. The financial statements, comprising the statement of income and expenditure, statement of financial position, statement of cash flows, statement of changes in fund, and accompanying notes, are in accordance with the ACNC Act 2012 and:
  - a) comply with Australian Accounting Standards – Reduced Disclosure Requirements and the ACNC Regulations 2014; and
  - b) give a true and fair view of the entity's financial position as at 31 December 2020 and of its performance for the period ended on that date.
2. In the directors'/responsible entity's opinion, there are reasonable grounds to believe that the entity will be able to pay its debts as and when they become due and payable.

On behalf of the directors by:



**Malcolm Day**

Director and Chairman  
29 June 2021



**Simon Martin**

Director and Vice-Chairman  
29 May 2021



Tel: +61 8 6382 4600  
Fax: +61 8 6382 4601  
www.bdo.com.au

38 Station Street  
Subiaco, WA 6008  
PO Box 700 West Perth WA 6872  
Australia

**DECLARATION OF INDEPENDENCE BY JARRAD PRUE TO THE DIRECTORS OF BREAST CANCER CARE WA INCORPORATED**

As lead auditor for the review of Breast Cancer Care WA Incorporated for the year ended 31 December 2020, I declare that, to the best of my knowledge and belief, there have been no contraventions of any applicable code of professional conduct in relation to the review.

A handwritten signature in black ink, appearing to read 'J Prue', written in a cursive style.

**Jarrad Prue**

Director

**BDO Audit (WA) Pty Ltd**

Perth, 29 June 2021

## INDEPENDENT AUDITOR'S REPORT

To the members of Breast Cancer Care WA Inc

### Report on the Audit of the Financial Report

#### Qualified opinion

We have audited the financial report of Breast Care Inc, (the Entity), which comprises the statement of financial position as at 31 December 2020 the statement of profit or loss and other comprehensive income, the statement of changes in equity and the statement of cash flows for the year then ended, and notes to the financial report, including a summary of significant accounting policies, and the responsible entities' declaration.

In our opinion, except for the effects of the matter described in the *Basis for qualified opinion* section of our report, the accompanying financial report of Breast Cancer Care WA Inc, is in accordance with Division 60 of the *Australian Charities and Not-for-profits Commission Act 2012*, including:

- (i) Giving a true and fair view of the registered entity's financial position as at 31 December 2020 and of its financial performance for the year then ended; and
- (ii) Complying with Australian Accounting Standards - Reduced Disclosure Requirements and Division 60 of the *Australian Charities and Not-for-profits Commission Regulation 2013*.

#### Basis for qualified opinion

Fundraising income (which includes Cash donations, fundraising programs, event income and sponsorship and grants) are a significant source of revenue for Breast Cancer Care WA Inc. The registered entity has determined that it is impracticable to establish control over the collection of Fundraising income prior to entry into its financial records. Accordingly, as the evidence available to us regarding fundraising revenue from this source was limited, our audit procedures with respect to fundraising income had to be restricted to the amounts recorded in the financial records amounting to \$692,045. We therefore are unable to express an opinion whether fundraising income recorded by the registered entity are complete.

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the Financial Report* section of our report. We are independent of the registered entity in accordance with the auditor independence requirements of the *Australian Charities and Not-for-profits Commission Act 2012* (ACNC Act) and the ethical requirements of the Accounting Professional and Ethical Standards Board's *APES 110 Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.



### **Other information**

Those charged with governance are responsible for the other information. The other information obtained at the date of this auditor's report is information included in the in Breast Cancer Care WA Inc's annual report, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### **Responsibilities of responsible entities for the Financial Report**

The responsible entities of the registered entity are responsible for the preparation and fair presentation of the financial report in accordance with Australian Accounting Standards - Reduced Disclosure Requirements and the ACNC Act, and for such internal control as the responsible entities determine is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error.

In preparing the financial report, responsible entities are responsible for assessing the registered entity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the responsible entities either intends to liquidate the registered entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the registered entity's financial reporting process.

### **Auditor's responsibilities for the audit of the Financial Report**

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.





A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website (<http://www.auasb.gov.au/Home.aspx>) at:

[http://www.auasb.gov.au/auditors\\_responsibilities/ar4.pdf](http://www.auasb.gov.au/auditors_responsibilities/ar4.pdf)

This description forms part of our auditor's report.

**BDO Audit (WA) Pty Ltd**

BDO

A handwritten signature in black ink, appearing to read 'J Prue'.

**Jarrad Prue**

**Director**

Perth, 29 June 2021



breast cancer  
care wa

Breast Cancer Care WA, 80 Railway Street, Cottesloe WA 6011  
PO Box 905, Cottesloe, WA 6911 | **ABN** 77 221 238 430 **DGR** 900 496 628  
**T** 08 9324 3703 | **F** 08 9284 6608 | [info@breastcancer.org.au](mailto:info@breastcancer.org.au)

[breastcancer.org.au](http://breastcancer.org.au)